Evidence map›Paper›PMID 33831450›Full record

ArticleInternational journal of biological macromolecules2021

Antiviral potential of plant polysaccharide nanoparticles actuating non-specific immunity.

Sergey V Stovbun, Tatiana S Kalinina, Dmitry V Zlenko, Aleksei V Kiselev, Alexander A Litvin, Alexander A Bukhvostov, Sergey V Usachev, Dmitry A Kuznetsov

Open access · greenAbstract read
In one paragraph

Article in International journal of biological macromolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Refined polysaccharide fromFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sergey V StovbunN.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
Tatiana S KalininaFederal State Budgetary Institution, Research Zakusov Institute of Pharmacology, Moscow, Russia.
Dmitry V ZlenkoN.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia; M.V. Lomonosov Moscow State University, Moscow, Russia; A.N. Severtsov Institute of Ecology and Evolution, Moscow, Russia. Electronic address: dvzlenko@gmail.com.
Aleksei V KiselevN.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
Alexander A LitvinFederal Research and Clinical Center of Physical-Chemical Medicine FMBA, Russia.
Alexander A BukhvostovN.I. Pirogov Russian, National Research Medical University, Moscow, Russia.
Sergey V UsachevN.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
Dmitry A KuznetsovN.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia; N.I. Pirogov Russian, National Research Medical University, Moscow, Russia.
Semenov Institute of Chemical Physics · RUPirogov Russian National Research Medical University · RUInstitute of Pharmacology Russian Academy of Medical Sciences · RUResearch Institute of Physical Chemical Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of high-end targeted drugs and vaccines against modern pandemic infections, such as COVID-19, can take a too long time that lets the epidemic spin up and harms society. However, the countermeasures must be applied against the infection in this period until the targeted drugs became available. In this regard, the non-specific, broad-spectrum anti-viral means could be considered as a compromise allowing overcoming the period of trial. One way to enhance the ability to resist the infection is to activate the nonspecific immunity using a suitable driving-up agent, such as plant polysaccharides, particularly our drug Panavir isolated from the potato shoots. Earlier, we have shown the noticeable anti-viral and anti-bacterial activity of Panavir. Here we demonstrate the pro-inflammation activity of Panavir, which four-to-eight times intensified the ATP and MIF secretion by HL-60 cells. This effect was mediated by the active phagocytosis of the Panavir particles by the cells. We hypothesized the physiological basis of the Panavir proinflammatory activity is mediated by the indol-containing compounds (auxins) present in Panavir and acting as a plant analog of serotonin.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentDrug CarriersNanoparticlesPolysaccharidesProbucolAdolescentAdultHL-60 CellsHumansMalePhagocytosisPlantsAntiviral AgentsDrug CarriersPolysaccharidesProbucolAntiviral activityCOVID-19Immune modulator

Identifiers

PMID33831450
PMCPMC8020621
OpenAlexW3151222590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.